Aclaris Therapeutics to host R&D Day on October 14

Aclaris Therapeutics (ACRS) will host it’s 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025 at 8:00 AM ET to discuss the Company’s progress in addressing therapeutic gaps in immuno-inflammatory markets. The event will feature presentations by Aclaris leadership and Zuzana Diamant, MD, PhD, FERS and Michael C. Cameron, MD, FAAD, who will highlight Aclaris’ development of kinase and immune pathway inhibitor franchises addressing therapeutically relevant, validated immune targets, and the markets and gaps the Company seeks to address. Among the topics that Aclaris leadership will discuss are: Aclaris’ work in developing uniquely potent small and large molecule product candidates to address significant gaps in important I&I indications; Perspectives on Aclaris’ innovative discovery technology platform, and its progress towards its goal of “drugging the undruggable” by targeting previously inaccessible components of the kinome and multiple pathways; Insights into the Company’s progress with its potential best-in-class ITK inhibition franchise; More on Aclaris’ TSLP franchise, and Aclaris’ progress in developing monoclonal and bispecific antibodies against validated targets; New updates on Aclaris’ execution on its ongoing clinical trials and on designing future clinical programs.